edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Actinogen Medical
Edison Investment Research has terminated coverage on Actinogen Medical (ACW). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.
Actinogen Medical — 7 videos in collection
Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11β-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.
In this interview, chief executive officer Dr Steven Gourlay describes the commercial opportunities and next development steps for Xanamem in Alzheimer’s disease (AD) and for CI in relation to major depressive disorder. He also discusses promising indications of therapeutic activity from a recent analysis of patients in its XanADu study in mild AD with confirmed disease through blood biomarker testing.
Get access to the very latest content matched to your personal investment style.